Scripps Florida Licenses Kinase Inhibitors To Poniard Pharma to Complete $2.5M SRA | GenomeWeb
The Scripps Research Institute has licensed to Poniard Pharmaceuticals a class of protein kinase inhibitors for treating a variety of diseases, capping a research collaboration begun in 2005, Poniard and Scripps said this week.
 
The agreement, which gives the drug maker access to a class of compounds that have shown anti-cancer activity, also marks the first time that Scripps Research Institute’s Florida facility has outlicensed a technology developed through an industry-sponsored research agreement.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.